Unknown Infection & Immunity NIHR-supported project
CVAY736S12201: A phase 2, randomized, double-blind study of ianalumab (VAY736) versus placebo in participants with diffuse cutaneous systemic sclerosis (dcSSc)
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Voon Ong (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A phase 2b/3 studyto investigate the efficacy and safety of ABBV-105 and Upadacitinib given alone or in combination (ABBV-599 combination) in subjects with diffuse cutaneous systemic sclerosis (dcSSc)
A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis
CVAY736F12302: A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of VAY736 (ianalumab) on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)
A Phase 2a, double-blind, randomised, placebo-controlled, efficacy, and safety study of multiple doses of VIT-2763 in subjects with Sickle Cell Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT 7117 in Subjects with Diffuse Cutaneous Systemic Sclerosis
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know